Acarix AB (publ) (STO:ACARIX)
Sweden · Delayed Price · Currency is SEK | Market Cap | 323.00M +44.6% |
| Revenue (ttm) | 8.06M +26.3% |
| Net Income | -42.76M |
| EPS | -0.04 |
| Shares Out | 1.19B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1,639,886 |
| Open | 0.2680 |
| Previous Close | 0.2720 |
| Day's Range | 0.2575 - 0.2715 |
| 52-Week Range | 0.2200 - 0.4710 |
| Beta | -0.26 |
| RSI | 41.10 |
| Earnings Date | May 18, 2026 |
About Acarix AB
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden. [Read more]
Financial Performance
In 2025, Acarix AB's revenue was 7.36 million, an increase of 18.69% compared to the previous year's 6.20 million. Losses were -48.09 million, -27.34% less than in 2024.
Financial StatementsNews
Q1 2026 Acarix AB Earnings Presentation Transcript
Q1 2026 Acarix AB Earnings Presentation Transcript
Acarix AB Earnings Call Transcript: Q1 2026
Revenue rose over 40% year-over-year, led by 90% U.S. growth on a constant currency basis, while gross margin held at 81% and operating costs fell 32%. Regulatory and reimbursement progress, strong clinical results, and expanding primary care adoption support a positive outlook.
Acarix AB Quarterly report: Q1 2026
Acarix AB has published its Q1 2026 quarterly earnings report on May 18, 2026.
Acarix AB Slides: Q1 2026
Acarix AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 18, 2026.
Acarix AB Earnings Call Transcript: Q1 2026
Revenue rose over 40% year-over-year, led by 90% U.S. growth on a constant currency basis, while gross margin held at 81% and operating costs fell 32%. Regulatory and reimbursement progress, strong clinical results, and expanding primary care adoption support a positive outlook.
Acarix AB Quarterly report: Q1 2026
Acarix AB has published its Q1 2026 quarterly earnings report on May 18, 2026.
Acarix AB Slides: Q1 2026
Acarix AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 18, 2026.
Acarix AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 26% revenue growth, led by 87% U.S. market expansion and 64% increase in CADScor deliveries. Operating costs fell 23%, net loss improved 27%, and patch sales rose 73%. New payer and MDR certification support further global growth.
Acarix AB Quarterly report: Q4 2025
Acarix AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Acarix AB Slides: Q4 2025
Acarix AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Acarix AB Annual report: Q4 2025
Acarix AB has published its Q4 2025 annual report on February 12, 2026.
Acarix AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 26% revenue growth, led by 87% U.S. market expansion and 64% increase in CADScor deliveries. Operating costs fell 23%, net loss improved 27%, and patch sales rose 73%. New payer and MDR certification support further global growth.
Acarix AB Quarterly report: Q4 2025
Acarix AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Acarix AB Slides: Q4 2025
Acarix AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Acarix AB Annual report: Q4 2025
Acarix AB has published its Q4 2025 annual report on February 12, 2026.
Acarix AB Earnings Call Transcript: Q3 2025
Q3 saw 137% global revenue growth, 95% increase in system deployments, and 49% reduction in net loss, driven by MENA expansion and robust U.S. performance. Gross margin remained strong at 85%, with expanding reimbursement and new clinical milestones.
Acarix AB Quarterly report: Q3 2025
Acarix AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
Acarix AB Slides: Q3 2025
Acarix AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Acarix AB Earnings Call Transcript: Q3 2025
Q3 saw 137% global revenue growth, 95% increase in system deployments, and 49% reduction in net loss, driven by MENA expansion and robust U.S. performance. Gross margin remained strong at 85%, with expanding reimbursement and new clinical milestones.
Acarix AB Quarterly report: Q3 2025
Acarix AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
Acarix AB Slides: Q3 2025
Acarix AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Acarix AB Earnings Call Transcript: Q2 2025
Q2 saw strong U.S. growth with a 27% increase in system deliveries and 53% patch sales growth in H1, while gross margin rose to 94% and operating costs fell 24%. Revenue declined due to European divestment, but new global distribution and reimbursement wins position the company for future profitability.
Acarix AB Quarterly report: Q2 2025
Acarix AB has published its Q2 2025 quarterly earnings report on August 21, 2025.
Acarix AB Slides: Q2 2025
Acarix AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 21, 2025.
Acarix AB Earnings Call Transcript: Q2 2025
Q2 saw strong U.S. growth with a 27% increase in system deliveries and 53% patch sales growth in H1, while gross margin rose to 94% and operating costs fell 24%. Revenue declined due to European divestment, but new global distribution and reimbursement wins position the company for future profitability.